Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Total Liabilities for 10 consecutive years, with $210.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 7.71% to $210.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $210.2 million through Dec 2025, down 7.71% year-over-year, with the annual reading at $210.2 million for FY2025, 7.71% down from the prior year.
  • Total Liabilities for Q4 2025 was $210.2 million at Rhythm Pharmaceuticals, roughly flat from $211.2 million in the prior quarter.
  • The five-year high for Total Liabilities was $239.2 million in Q2 2025, with the low at $33.6 million in Q3 2021.
  • Average Total Liabilities over 5 years is $140.5 million, with a median of $142.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 223.06% in 2022, then fell 7.71% in 2025.
  • Over 5 years, Total Liabilities stood at $45.4 million in 2021, then skyrocketed by 160.55% to $118.2 million in 2022, then surged by 37.87% to $163.0 million in 2023, then surged by 39.72% to $227.7 million in 2024, then decreased by 7.71% to $210.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $210.2 million, $211.2 million, and $239.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.